{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:04:27Z","timestamp":1772604267232,"version":"3.50.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of the Report<\/jats:title>\n            <jats:p>The aim of this study was to evaluate safety and efficacy of copper-64(II)dichloride (<jats:sup>64<\/jats:sup>Cu(II)Cl<jats:sub>2<\/jats:sub>) as a new PET tracer for urological malignancies (UMs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients with UM were enrolled in a prospective study. All patients were staged with preoperative CT and <jats:sup>64<\/jats:sup>Cu(II)Cl<jats:sub>2<\/jats:sub> PET\/CT. Patient characteristics, anatomical and functional imaging, and final histopathology were recorded. Surgical specimens for histopathological examination were collected. To determine time-activity curves for <jats:sup>64<\/jats:sup>Cu(II)Cl<jats:sub>2<\/jats:sub> uptake in UM and normal tissues, SUVs were calculated. The safety of <jats:sup>64<\/jats:sup>Cu(II)Cl<jats:sub>2<\/jats:sub> was assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Twenty-three patients were included. An administered activity of 174.7 MBq (4.72 mCi) for <jats:sup>64<\/jats:sup>Cu(II)Cl<jats:sub>2<\/jats:sub> was equal to 9.80 mSv of the effective dose. The median SUVmax values were 5.7, 0.9, 1.8, and 9.8 for the prostate, bladder, penis, and kidney, respectively. Median SUVmax values were higher in organs with a malignancy in comparison with healthy tissue (prostate [11.5 vs 5.3, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001], bladder [6.2 vs 0.9, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.007], and penis [3.9 vs 1.3, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.027]), but not in the kidneys (5.0 vs 10.4, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.998). The highest area under the curve (AUC) was reported for prostate cancer (AUC, 0.978), and the lowest for penile cancer (AUC, 0.775). The detection rates based on the best suggested cutoff according to the SUVmax were 85.7% (6\/7) for prostate and bladder and 83.3% (5\/6) for penile cancer. Neither drug-related effects nor physiologic responses occurred, nor adverse reactions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>\n                                 <jats:sup>64<\/jats:sup>Cu(II)Cl<jats:sub>2<\/jats:sub> is an effective and well-tolerated tracer in patients with UM. Our results show higher SUVmax in cancer patients than in healthy subjects. Our findings suggest that <jats:sup>64<\/jats:sup>Cu(II)Cl<jats:sub>2<\/jats:sub> PET\/CT is useful in patients affected by prostate, bladder, and penis cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000003658","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T15:58:02Z","timestamp":1619107082000},"page":"443-448","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy and Safety of the 64Cu(II)Cl2 PET\/CT for Urological Malignancies"],"prefix":"10.1097","volume":"46","author":[{"given":"Manlio","family":"Mascia","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine and Radiometabolic Therapy, \u201cSpirito Santo\u201d Hospital, Pescara"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Villano","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Radiometabolic Therapy, \u201cSpirito Santo\u201d Hospital, Pescara"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio","family":"De Francesco","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Radiometabolic Therapy, \u201cSpirito Santo\u201d Hospital, Pescara"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Schips","sequence":"additional","affiliation":[{"name":"Department of Medical, Oral and Biotechnological Sciences, Urology Unit, SS Annunziata Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Marchioni","sequence":"additional","affiliation":[{"name":"Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, \u201cG. d\u2019Annunzio\u201d University of Chieti, Chieti"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Cindolo","sequence":"additional","affiliation":[{"name":"Department of Urology, Villa Stuart Private Hospital, Rome, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2174\/138161209787582183","article-title":"Metal complexes, their cellular targets and potential for cancer therapy","volume":"15","year":"2009","journal-title":"Curr Pharm Des"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jtemb.2004.02.004","article-title":"Role of copper in tumour angiogenesis\u2014clinical implications","volume":"18","year":"2004","journal-title":"J Trace Elem Med Biol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000438485","article-title":"Behind the link between copper and angiogenesis: established mechanisms and an overview on the role of vascular copper transport systems","volume":"52","year":"2015","journal-title":"J Vasc Res"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1039\/C5MT00149H","article-title":"Targeting copper in cancer therapy: \u2018copper that cancer\u2019","volume":"7","year":"2015","journal-title":"Metallomics"},{"key":"bib5-20250621","first-page":"1015","article-title":"Positron emission tomography of altered copper metabolism for metabolic imaging and personalized therapy of prostate cancer","volume":"1","year":"2013","journal-title":"J Radiol Radiat Ther"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s12149-015-0968-4","article-title":"Role of 64CuCl2 PET\/CT in staging of prostate cancer","volume":"29","year":"2015","journal-title":"Ann Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2967\/jnumed.117.195628","article-title":"64CuCl2 PET\/CT in prostate cancer relapse","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib8-20250621","first-page":"159","article-title":"Imaging of brain tumors with copper-64 chloride: early experience and results","volume":"31","year":"2016","journal-title":"Cancer Biother Radiopharm"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.urolonc.2017.04.014","article-title":"Advances in medical imaging for the diagnosis and management of common genitourinary cancers","volume":"35","year":"2017","journal-title":"Urol Oncol"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"e696","DOI":"10.1016\/S1470-2045(18)30604-1","article-title":"Consensus on molecular imaging and theranostics in prostate cancer","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/iju.13779","article-title":"Positron-emission tomography imaging in urological oncology: current aspects and developments","volume":"25","year":"2018","journal-title":"Int J Urol"},{"issue":"suppl 1","key":"bib13-20250621","first-page":"S18","article-title":"18F-choline, 11C-choline and 11C-acetate PET\/CT: comparative analysis for imaging prostate cancer patients","volume":"40","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/j.1464-410X.2012.11150.x","article-title":"[18F]fluoromethylcholine (FCH) positron emission tomography\/computed tomography (PET\/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients","volume":"110","year":"2012","journal-title":"BJU Int"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.urology.2017.04.019","article-title":"Diagnostic accuracy of 64copper prostate-specific membrane antigen positron emission tomography\/computed tomography for primary lymph node staging of intermediate- to high-risk prostate cancer: our preliminary experience","volume":"106","year":"2017","journal-title":"Urology"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s12325-018-0711-3","article-title":"Application of Cu-64 NODAGA-PSMA PET in prostate cancer","volume":"35","year":"2018","journal-title":"Adv Ther"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1021\/ar800255q","article-title":"Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET)","volume":"42","year":"2009","journal-title":"Acc Chem Res"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T21:03:14Z","timestamp":1750539794000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003658"}},"subtitle":["Phase IIa Clinical Study"],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003658","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,21]]}}}